Truncated Complement Factor H Y402 Gene Therapy Cures C3 Glomerulonephritis

Area of Science:

• Ophthalmology
• Nephrology
• Gene Therapy

Background:

• Age-related macular degeneration (AMD) and C3 glomerulonephritis (C3G) share complement dysregulation pathways.
• Current therapies for C3G are limited, and previous attempts using exogenous complement factor H (CFH) faced immune rejection.
• C3G is characterized by complement alternative pathway dysregulation.

Purpose of the Study:

• To investigate adeno-associated virus (AAV)-mediated delivery of truncated CFH (tCFH) for treating C3G.
• To assess the efficacy and long-term safety of AAV-tCFH gene therapy in a mouse model.
• To explore AAV-tCFH as a potential therapy for both C3G and AMD.

Main Methods:

• Utilized a Cfh-/- mouse model of C3G.
• Administered various adeno-associated virus (AAV) vectors encoding truncated complement factor H (tCFH).
• Monitored complement pathway inhibition, disease reversal, and immune response.

Main Results:

• Long-term AAV-mediated delivery of tCFH successfully inhibited the complement alternative pathway.
• Reversal of C3G was achieved without evidence of immune rejection.
• Different AAV vectors demonstrated varying levels of efficiency and efficacy.

Conclusions:

• AAV-mediated tCFH gene therapy offers a promising strategy for C3G treatment, overcoming limitations of previous approaches.
• This study provides proof of concept for AAV-tCFH gene augmentation therapy for AMD.
• The findings support the development of novel gene therapies targeting complement dysregulation in both C3G and AMD patients.